01.23.2017 - By Clarivate Analytics – Formerly the IP&Science business of Thomson Reuters
The recent buzz around CRISPR-Cas9, a genome editing tool, has revolved around its potential for treating various genetic diseases, including cancer. Jack Hopwood, Intellectual Property Consultant and Bertrand Sautier, Strategic Account Manager at Clarivate Analytics talk about how research activity around CRISPR is being measured by tracking R&D strategies and patents. You will also hear about the importance of protecting intellectual property to help accelerate the pace of innovation and minimize the risk of running into costly disputes.